Vaccine.

India's top tuberculosis fighter said the government will expand access to Johnson & Johnson's breakthrough TB drug this year, but health experts warn much more needs to be done to eliminate the superbug by 2025. India will make bedaquiline, one of just two new TB drugs marketed over the last 50 years, available at 140 government-run TB treatment centers by November, said Sunil Kharpade, head of India's Central TB Division.

Outdated vaccine supply and distribution systems are delaying and limiting the impact of vaccines, placing the health of millions of people at risk, according to new articles published in Vaccine journal. The researchers note that one in every three countries in the world experiences at least one stockout of at least one vaccine for at least one month, while 19 to 38 per cent of vaccines worldwide are accidentally exposed to freezing temperatures, potentially compromising the potency of those vaccines.

A special supplement to the journal Vaccine published yesterday aims to measure the biggest challenges to global vaccine campaigns today, noting that vaccine stockouts—or complete unavailability of vaccines—occur at least monthly, while 19% to 38% of vaccines worldwide are subjected to improper refrigeration practices.

Imagine a vaccine vial with a temperature-sensitive label that changes colors when exposed to excessive heat. That's the sort of technology that can make a huge difference for doctors working in challenging conditions, allowing them to determine at-a-glance whether heat-sensitive vaccines are viable.

A cancer with an effective vaccine is killing thousands of women. Last year, nearly 70,000 Indians died of cervical cancer, more than anywhere else in the world. It’s the second-most common cancer among women in the country, accounting for 23% of all cases. It’s a hidden disease, often taking 20 years to show itself.

Today, a human trial for a malaria vaccine reported up to 100% protection for ten weeks following the last dose, a potential breakthrough for a vexing disease. While this vaccine has been trialed before, it has never been this effective. The key appears to be how the vaccine was delivered—directly into the bloodstream as opposed to into a muscle, as most vaccines are.

A next-generation vaccine that uses a weakened form of a malaria parasite has shown efficacy and safety in a small number of humans, according to a new study published in Science Translational Medicine. With this development researchers of the vaccine called GAP3KO might have achieved a milestone in malaria vaccine development.

An Ebola vaccine that has been in development for 15 years has been shown in a clinical trial to be up to 100 percent effective at preventing the deadly virus. But it won’t stop sporadic cases from popping up, nor will it be immediately available to some who are most vulnerable to the virus.